A novel recombinant anti‐epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model

Asadi-Ghalehni, Majid; Rasaee, Mohammad Javad; Rajabibazl, Masoumeh; Khosravani, Masood; Motaghinejad, Majid; Javanmardi, Masoud; Khalili, Saeed; Modjtahedi, Helmout; Sadroddiny, Esmaeil

doi:10.1111/1348-0421.12547

Cited by 8 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we explored engineered M13 bacteriophages with a pIII display (pIII::MAGE-A1) and engineered M13 bacteriophages with a pVIII display (pVIII::MAGE-A1) to investigate whether the display method significantly affects adaptive immunity. The vaccines employing phage display were previously designed on either the pVII or pIII protein [ 10 , 42 , 44 , 45 , 46 , 49 ]. The existing literature lacks a comparative assessment of these two approaches.…”

Section: Discussionmentioning

confidence: 99%

An Engineered M13 Filamentous Nanoparticle as an Antigen Carrier for a Malignant Melanoma Immunotherapeutic Strategy

Brišar,

Šuster,

Brezar

et al. 2024

Viruses

View full text Add to dashboard Cite

Bacteriophages, prokaryotic viruses, hold great potential in genetic engineering to open up new avenues for vaccine development. Our study aimed to establish engineered M13 bacteriophages expressing MAGE-A1 tumor peptides as a vaccine for melanoma treatment. Through in vivo experiments, we sought to assess their ability to induce robust immune responses. Using phage display technology, we engineered two M13 bacteriophages expressing MAGE-A1 peptides as fusion proteins with either pVIII or pIIII coat proteins. Mice were intraperitoneally vaccinated three times, two weeks apart, using two different engineered bacteriophages; control groups received a wild-type bacteriophage. Serum samples taken seven days after each vaccination were analyzed by ELISA assay, while splenocytes harvested seven days following the second boost were evaluated by ex vivo cytotoxicity assay. Fusion proteins were confirmed by Western blot and nano-LC-MS/MS. The application of bacteriophages was safe, with no adverse effects on mice. Engineered bacteriophages effectively triggered immune responses, leading to increased levels of anti-MAGE-A1 antibodies in proportion to the administered bacteriophage dosage. Anti-MAGE-A1 antibodies also exhibited a binding capability to B16F10 tumor cells in vitro, as opposed to control samples. Splenocytes demonstrated enhanced CTL cytotoxicity against B16F10 cells. We have demonstrated the immunogenic capabilities of engineered M13 bacteriophages, emphasizing their potential for melanoma immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

An Engineered M13 Filamentous Nanoparticle as an Antigen Carrier for a Malignant Melanoma Immunotherapeutic Strategy

Brišar,

Šuster,

Brezar

et al. 2024

Viruses

View full text Add to dashboard Cite

show abstract

“…Immunization of mice with Lewis lung carcinoma (C57/BL6) with peptide‐phage vaccine resulted in the production of antibodies against EM‐L2 and decreased the tumor growth rate by about 25%. Based on these promising findings, this therapeutic strategy can be of high importance in contemporary cancer immunotherapy 48 …”

Section: Bacteriophage Applications In Medical Oncologymentioning

confidence: 99%

“…Based on these promising findings, this therapeutic strategy can be of high importance in contemporary cancer immunotherapy. 48…”

Section: Bacteriophage Application In Cancer Vaccinationmentioning

confidence: 99%

New role of bacteriophages in medical oncology

Moradi,

Ghaleh,

Bolandian

et al. 2023

Biotech and App Biochem

View full text Add to dashboard Cite

Targeted treatment of cancer is one of the most paramount approaches in cancer treatment. Despite significant advances in cancer diagnosis and treatment methods, there are still significant limitations and disadvantages in the field, including high costs, toxicity, and unwanted damage to healthy cells. The phage display technique is an innovative method for designing carriers containing exogenic peptides with cancer diagnostic and therapeutic properties. Bacteriophages possess unique properties making them effective in cancer treatment. These characteristics include the small size enabling them to penetrate vessels; having no pathogenicity to mammals; easy manipulation of their genetic information and surface proteins to introduce vaccines and drugs to cancer tissues; lower cost of large‐scale production; and greater stimulation of the immune system. Bacteriophages will certainly play a more effective role in the future of medical oncology; however, studies are in the early stages of conception and require more extensive research. We aimed in this review to provide some related examples and bring insights into the potential of phages as targeted vectors for use in cancer diagnosis and treatment, especially regarding their capability in gene and drug delivery to cancer target cells, determination of tumor markers, and vaccine design to stimulate anticancer immunity.

show abstract

“…These mimotopes have been selected for their specific fit with antitumor-associated antigen antibodies as they are more efficient than natural epitopes. For instance, the EM.L2 peptide (QHYNIVNTQSRV) fused with the L2 extracellular domain of human EGFR was expressed in phages, and the phages were tested in a mouse model of lung carcinoma, resulting in the activation of humoral and cellular responses and inhibition of tumor growth [ 160 , 199 ]. Phage display panning was also performed in mice bearing melanoma tumors, and a specific ligand WDC-2 (displaying the TRTKLPRLHLQS peptide motif) was identified in B16-F10 cells, which exhibited complete regression of the established tumors and long-term survival [ 161 ].…”

Section: Revolutionary Strategy Of Engineered Bacteriophages For Comb...mentioning

confidence: 99%

Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions

Ragothaman

Yoo

2023

Vaccines

View full text Add to dashboard Cite

Bacteriophages have emerged as versatile tools in the field of bioengineering, with enormous potential in tissue engineering, vaccine development, and immunotherapy. The genetic makeup of phages can be harnessed for the development of novel DNA vaccines and antigen display systems, as they can provide a highly organized and repetitive presentation of antigens to immune cells. Bacteriophages have opened new possibilities for the targeting of specific molecular determinants of cancer cells. Phages can be used as anticancer agents and carriers of imaging molecules and therapeutics. In this review, we explored the role of bacteriophages and bacteriophage engineering in targeted cancer therapy. The question of how the engineered bacteriophages can interact with the biological and immunological systems is emphasized to comprehend the underlying mechanism of phage use in cancer immunotherapy. The effectiveness of phage display technology in identifying high-affinity ligands for substrates, such as cancer cells and tumor-associated molecules, and the emerging field of phage engineering and its potential in the development of effective cancer treatments are discussed. We also highlight phage usage in clinical trials as well as the related patents. This review provides a new insight into engineered phage-based cancer vaccines.

show abstract

A novel recombinant anti‐epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model

Cited by 8 publications

References 42 publications

An Engineered M13 Filamentous Nanoparticle as an Antigen Carrier for a Malignant Melanoma Immunotherapeutic Strategy

An Engineered M13 Filamentous Nanoparticle as an Antigen Carrier for a Malignant Melanoma Immunotherapeutic Strategy

New role of bacteriophages in medical oncology

Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions

Contact Info

Product

Resources

About